Bod Australia
Bod Australia (ASX: BOD) is a Sydney-based, publicly listed medicinal cannabis company that supplies prescription-only cannabinoid medicines including Bod MediCabilis to Australian pharmacies and clinics, serving patients with chronic conditions across seven therapeutic indications.
- Company typePrivate
- Founded2016
- HeadquartersSydney, Australia
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bod Australia does
Bod Australia (ASX: BOD) is a Sydney-based, publicly listed medicinal cannabis company founded in 2016 that develops, supplies, and clinically researches prescription-only cannabinoid-based medicines for the Australian market. The company's core product is Bod MediCabilis, supplemented by a portfolio of medicinal cannabis formulations across multiple delivery formats including oils (the dominant delivery method), capsules, dry flower, oromucosal spray, lozenges, and creams. Bod invests in clinical research across seven therapeutic indications — chronic pain, anxiety, stress, depression, epilepsy, arthritis, and inflammation — and is actively recruiting participants for the CAN-REST insomnia study using cannabinoid-based medications.
The company operates a B2B2C distribution model in which licensed pharmacies order Bod's prescription cannabis products directly upon receipt of approved prescriptions, while partner medical clinics assess patient eligibility and issue prescriptions through a doctor support program. Bod generates revenue primarily through prescription medicinal cannabis sales priced at the pharmacy level, with pricing not publicly disclosed. The company is headquartered in Australia, employs 11-50 people, and serves two primary customer segments: patients with chronic conditions seeking cannabinoid-based treatment after standard options have been exhausted, and the healthcare professionals (doctors and clinic partners) who prescribe these treatments.
From a corporate governance and operational perspective, Bod Australia is led by founder and CEO Jo Patterson, CFO Adrian Sturrock, and CTO Craig Weller. The business is positioned at the intersection of regulated pharmaceutical distribution, clinical evidence generation, and prescriber education within Australia's controlled medicinal cannabis framework, with no disclosed AI or proprietary technology platform beyond its pharmaceutical formulations and pharmacy ordering infrastructure.
Bod Australia firmographics
Firmographics- Name
- Bod Australia
- Legal name
- Bod Australia
- Website
- https://bodaustralia.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Bod Australia (ASX: BOD) is a Sydney-based, publicly listed medicinal cannabis company that supplies prescription-only cannabinoid medicines including Bod MediCabilis to Australian pharmacies and clinics, serving patients with chronic conditions across seven therapeutic indications.
- Ownership category
- akta.pro rank
Bod Australia industry classification
Industry- Product category
- Medicinal Cannabis Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Medical Cannabis Dispensaries (CRANAFAB)
- akta.pro secondary industry
- CBD/Hemp Wellness & Supplements Retail (CRANAHAC)
Keywords
Where Bod Australia is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Bod Australia business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
Revenue model
- Prescription Medicinal Cannabis Sales: Bod Science generates revenue through the sale of prescription-only medicinal cannabis products, primarily Bod MediCabilis, distributed through pharmacies. Healthcare providers prescribe the medication after patient assessment, and pharmacies order directly from Bod upon receiving approved prescriptions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Prescription-based pricing through pharmacies |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Bod Australia product offering
Product offeringCore offering
Bod Australia develops, manufactures, and distributes prescription-only medicinal cannabis products under the Bod Science brand, with Bod MediCabilis as the flagship prescription medicine offered in multiple delivery formats including oils, capsules, dry flower, oromucosal sprays, lozenges, and creams. The company also conducts clinical research on cannabinoid-based therapies, including the CAN-REST study for chronic insomnia, and distributes its products through a national pharmacy network of more than 3,000 locations in Australia.
Product overview
Bod Australia operates as a medicinal cannabis company offering a portfolio of prescription-only cannabis-based medicines. The core product is Bod MediCabilis, supplemented by a range of medicinal cannabis delivery formats including oils, capsules, dry flower, oromucosal spray, lozenges, and creams. The company also conducts clinical trials and research (such as the CAN-REST insomnia study) and provides doctor support services to facilitate patient access to medicinal cannabis treatments for chronic conditions.
Differentiator
Problem solved
Functional benefit
Brands
- Bod MediCabilis: Prescription-only medicinal cannabis medicine offered by the company through pharmacy ordering.
Products and services
- Bod MediCabilis
- Medicinal Cannabis Product Range A range of Bod MediCabilis medicinal cannabis delivery formats — oils, capsules, dry flower, oromucosal sprays, lozenges, and creams — manufactured and supplied to Australian pharmacies to meet varied patient and prescriber preferences.
- Clinical Trials and Research Services Clinical research conducted by Bod Science, including the CAN-REST trial evaluating medicinal cannabis for chronic insomnia, generating clinical evidence to support prescribing and product claims.
Quantifiable outcome
- Medicinal cannabis can be prescribed for any chronic indication where supporting clinical evidence exists
Companies that use Bod Australia
Customer profileSegments3 records
Ideal customer profiles2 records
Bod Australia technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Bod Australia partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Pharmacy PartnerscoreBod Science maintains direct relationships with pharmacies across Australia that dispense Bod MediCabilis and other medicinal cannabis products. Pharmacies order directly from Bod once prescriptions are approved and received, creating a streamlined distribution channel.
- Medical ClinicscorePartner medical clinics assess patient eligibility and prescribe medicinal cannabis treatments. The company supports these clinical partners through its doctor support program, providing educational resources and expert care coordination for patients seeking cannabinoid-based treatments.
Scale indicators2 records
Recent moves6 records
Expansion highlights4 records
Bod Australia competitors and assessment
Company assessmentDirect peers
- Little Green Pharma: ASX-listed Australian medicinal cannabis manufacturer and distributor offering a comparable range of cannabis oil and flower products through pharmacy channels, directly competing with Bod MediCabilis for the same prescriber base.
- Cann Group: Australian licensed medicinal cannabis producer (ASX: CAN) supplying cultivated and manufactured cannabis products to patients via prescription — overlapping with Bod's product portfolio and pharmacy distribution model.
- Auscann Group Holdings: ASX-listed Australian medicinal cannabis company developing and supplying cannabinoid-based pharmaceutical products for human and animal health, competing in the same domestic prescription cannabis market as Bod.
- THC Global Group: Australian medicinal cannabis manufacturer with pharmacy-distributed product lines, including oils and capsules, directly overlapping with Bod's prescription cannabis offering and distribution model.
- Althea Group: Australian medicinal cannabis company historically operating a similar pharmacy-distributed, prescriber-education-driven model to Bod, with overlapping product formats (oils, flowers) and chronic-condition therapeutic focus.
Emerging players
- Incannex Healthcare: ASX-listed clinical-stage Australian cannabinoid and psychedelic medicine developer. Overlaps with Bod in cannabinoid-based prescription therapeutics and clinical research focus, though targeting different product formats (e.g., psilocybin plus CBD combinations).
- Zelira Therapeutics: Australia-based (ASX: ZLD) cannabinoid medicine company with clinical programs across insomnia, pain, and other indications, overlapping with Bod's research-driven commercial strategy and prescription product positioning.
Broad incumbents
- Tilray Brands: Global large-scale cannabis producer with established Australian distribution. Offers a much broader portfolio of medical and recreational cannabis products, applying scale and capital advantages that pressure smaller Australian players like Bod.
- Jazz Pharmaceuticals (GW Pharmaceuticals): Owner of the pioneering cannabinoid pharmaceutical Sativex and Epidiolex, representing a global regulatory and clinical benchmark for prescription cannabis medicines that frames the competitive ceiling for companies like Bod.
Others
- IDT Australia: ASX-listed Australian pharmaceutical manufacturer providing contract manufacturing and formulation services relevant to the medicinal cannabis supply chain — adjacent infrastructure rather than a direct competitor, but comparable as an Australian pharma platform.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Bod Australia social profiles
Digital presenceBod Australia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bod Australia leadership team
Management profileNumber of profiles
Profiles3 records
Bod Australia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bod Australia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bod Australia
What does Bod Australia do?
Bod Australia develops, manufactures, and distributes prescription-only medicinal cannabis products under the Bod Science brand, with Bod MediCabilis as the flagship prescription medicine offered in multiple delivery formats including oils, capsules, dry flower, oromucosal sprays, lozenges, and creams. The company also conducts clinical research on cannabinoid-based therapies, including the CAN-REST study for chronic insomnia, and distributes its products through a national pharmacy network of more than 3,000 locations in Australia.
When was Bod Australia founded?
Bod Australia was founded in 2016. It employs 11 to 50 people.
Where is Bod Australia based?
Bod Australia is headquartered in Sydney, Australia, in the Oceania region.
How does Bod Australia make money?
One revenue line is on record: prescription Medicinal Cannabis Sales.
Who are Bod Australia's main competitors?
Direct peers on record are Little Green Pharma, Cann Group, Auscann Group Holdings, THC Global Group and Althea Group. Emerging players are Incannex Healthcare and Zelira Therapeutics. Broad incumbents are Tilray Brands and Jazz Pharmaceuticals (GW Pharmaceuticals). IDT Australia is listed as an others.
Does Bod Australia have an API?
No public API is recorded for Bod Australia.
What industry is Bod Australia in?
Bod Australia's product category is Medicinal Cannabis Pharmaceuticals. Its primary akta.pro industry code is CRANAFAB, Medical Cannabis Dispensaries, with a secondary code of CRANAHAC, CBD/Hemp Wellness & Supplements Retail. Its NAICS code is 325412 and its SIC code is 2834.